These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 4036867)

  • 1. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization.
    Scialla SJ
    Am J Clin Pathol; 1985 Sep; 84(3):351-4. PubMed ID: 4036867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions.
    Poller L; Thomson JM; Taberner DA
    Ric Clin Lab; 1989; 19(4):363-70. PubMed ID: 2633304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.
    D'Angelo A; Seveso MP; D'Angelo SV; Gilardoni F; Dettori AG; Bonini P
    Am J Clin Pathol; 1990 Sep; 94(3):297-306. PubMed ID: 2396604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor.
    Despotis GJ; Hogue CW; Santoro SA; Joist JH; Barnes PW; Lappas DG
    Crit Care Med; 1995 Oct; 23(10):1674-9. PubMed ID: 7587232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma.
    Zanke B; Shojania AM
    Am J Clin Pathol; 1990 May; 93(5):684-9. PubMed ID: 2183588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
    Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
    Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oral anticoagulant therapy on APTT results from a bedside coagulation monitor.
    Ray MJ; Carroll PA; Just SJ; Hawson GA; Bett JH
    J Clin Monit; 1994 Mar; 10(2):97-100. PubMed ID: 8207459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-blood clotting time, activated partial thromboplastin time, and whole-blood recalcification time as heparin monitoring tests.
    Ts'ao CH; Galluzzo TS; Lo R; Peterson KG
    Am J Clin Pathol; 1979 Jan; 71(1):17-21. PubMed ID: 420167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
    Harenberg J; Reichel T; Malsch R; Hirsh J; Rustagi P
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):453-8. PubMed ID: 8839997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: where should we go?
    van den Besselaar AM
    Ric Clin Lab; 1989; 19(4):371-7. PubMed ID: 2633305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
    Lang M; Fey MF; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.